Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- COVID 19 Pneumonia
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04449588
- Collaborators
- Beijing Defengrui Biotechnology Co. Ltd
- Investigators
- Principal Investigator: Qing Mao, Ph.D Southwest Hospital of Chongqing
Get Well Soon